Revenue and Profitability - Total revenue for the nine months ended September 30, 2024, was RMB 263,646,520.16, representing a 76.09% increase compared to the same period last year[4] - Net profit attributable to shareholders for the reporting period was RMB 2,964,467.27, a significant recovery from a loss of RMB 222,409,418.57 in the previous year[4] - Basic earnings per share for the current period was RMB 0.01, compared to a loss of RMB 0.90 per share in the same period last year[5] - The company's operating revenue for the year-to-date period increased by 222.88%, reaching 238,757,612.38 CNY, with a year-on-year growth of 36.85% after excluding the impact of COVID-19 vaccine returns[9] - Sales revenue from the meningococcal vaccine product reached 516,153,650.93 CNY, representing a year-on-year increase of 39.07%[9] - The net loss attributable to shareholders of the listed company for the first three quarters was 222,409,418.57 CNY, significantly reduced by 762,620,235.90 CNY compared to the previous year[9] - The company achieved a single-quarter net profit attributable to shareholders of 2,964,467.27 CNY in the third quarter[9] - Total revenue for the first three quarters of 2024 was a loss of 227,196,536.24 RMB, compared to a loss of 1,454,919,925.84 RMB in the same period of 2023, indicating a significant improvement[23] - Operating profit for the first three quarters of 2024 was a loss of 222,830,476.31 RMB, compared to a loss of 1,415,383,868.45 RMB in the same period of 2023, reflecting a reduction in operational losses[23] - Total comprehensive income attributable to the parent company for the first three quarters of 2024 was a loss of (226,815,781.51) RMB, compared to a loss of (1,454,797,112.46) RMB in the same period of 2023[25] Assets and Liabilities - Total assets as of September 30, 2024, were RMB 7,989,566,970.77, a decrease of 14.26% from RMB 9,318,769,372.66 at the end of the previous year[5] - As of September 30, 2024, total current assets were RMB 4,369,254,431.78, down from RMB 5,180,827,776.61 at the end of 2023, reflecting a decline of about 16%[18] - Total non-current assets decreased to RMB 3,620,312,538.99 from RMB 4,137,941,596.05, representing a reduction of approximately 12.5%[19] - Total liabilities as of September 30, 2024, were RMB 2,926,151,613.50, down from RMB 4,031,354,058.75, indicating a decrease of about 27%[20] - The company's total assets decreased to RMB 7,989,566,970.77 from RMB 9,318,769,372.66, reflecting a decline of approximately 14.2%[21] - The company's retained earnings showed a negative balance of RMB (1,780,823,276.18) as of September 30, 2024, compared to RMB (1,558,413,857.61) at the end of 2023[21] - Cash and cash equivalents decreased to RMB 1,364,455,953.58 from RMB 2,821,595,241.10, a decline of approximately 52%[18] - Short-term borrowings were reduced to RMB 596,881,991.30 from RMB 854,082,887.35, indicating a decrease of about 30%[20] Research and Development - Research and development expenses totaled RMB 107,918,795.43, a decrease of 23.18% compared to the same period last year[5] - The ratio of R&D expenses to total revenue was 40.93%, down 52.89 percentage points from the previous year[5] - Research and development expenses as a percentage of operating revenue decreased by 210.45 percentage points compared to the previous year[12] - Research and development expenses for the first three quarters of 2024 amounted to RMB 272,272,224.71, a decrease of approximately 41% compared to RMB 461,673,523.32 in 2023[22] Cash Flow - The company reported a net cash flow from operating activities of RMB (287,414,483.35), indicating ongoing challenges in cash generation[4] - Cash flow from operating activities for the first three quarters of 2024 was a net outflow of 287,414,483.35 RMB, an improvement from a net outflow of 748,974,021.75 RMB in the same period of 2023[28] - The company’s cash outflow for operating activities totaled 897,365,298.94 RMB in the first three quarters of 2024, down from 1,364,783,068.46 RMB in the same period of 2023, indicating improved cash management[28] - Cash inflow from investment activities for the first three quarters of 2024 was 9,594,480,245.55 RMB, compared to 6,640,825,701.63 RMB in the same period of 2023, showing a substantial increase[28] - Cash inflow from financing activities for the first three quarters of 2024 was approximately $709.2 million, a decrease of 48.5% compared to $1.32 billion in the same period of 2023[29] - Cash outflow for debt repayment in the first three quarters of 2024 was approximately $884.9 million, down 37.1% from $1.41 billion in the first three quarters of 2023[29] - Net cash flow from financing activities for the first three quarters of 2024 was negative $232.9 million, compared to negative $131.3 million in the same period of 2023[29] - The ending cash and cash equivalents balance for the first three quarters of 2024 was approximately $868.9 million, a decrease of 63.0% from $2.35 billion at the end of the same period in 2023[29] - The impact of exchange rate changes on cash and cash equivalents was negative $882.2 thousand in the first three quarters of 2024, contrasting with a positive impact of $51.8 million in the same period of 2023[29] Government Subsidies and Non-Recurring Items - The company received government subsidies amounting to RMB 14,565,011.91, which are not included in non-recurring gains and losses[6] - The total non-recurring gains and losses for the current period amounted to RMB 9,686,646.95, compared to RMB 38,838,797.88 for the previous period[7] - Other comprehensive income after tax for the first three quarters of 2024 was 380,754.73 RMB, significantly higher than 122,813.38 RMB in the same period of 2023[24] - The company reported investment losses of (50,473,598.71) RMB in the first three quarters of 2024, a decline from investment income of 71,754,545.48 RMB in the same period of 2023[23] - The company incurred asset impairment losses of (10,101,389.63) RMB in the first three quarters of 2024, a significant decrease from (786,743,942.29) RMB in the same period of 2023[23] - The average return on equity increased by 2.52 percentage points for the reporting period[10] - The weighted average return on net assets was 0.06%, an increase of 2.52 percentage points from the previous year[5]
康希诺生物(06185) - 2024 Q3 - 季度业绩